Ergomed taps former TFS executive for chief commercial officer

Pharmaceutical services firm Ergomed appointed former TFS International global sales and marketing head Roy Ovel as its next chief commercial officer on Monday.

Ovel, who has spent more than three decades in international business development with a number of the global contract research organisations, will be responsible for global sales and business development activities across the company's full services offering.

The AIM-listed firm said Ovel's focus will be on the benefits to customers of bringing together Ergomed's expertise in pharmacovigilance and orphan drug development.

Chairman Dr Miroslav Reljanović said: "Roy brings a wealth of experience to Ergomed. He has a proven track record in building commercial success through an understanding of customer's needs and delivering growth.

"I am confident that operating across the Ergomed business he will make a significant contribution to the company through the services we provide our clients."

As of 0845 GMT, Ergomed shares had dipped just 0.0060% to 166.49p.